Entera Bio Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011429839
USD
2.11
-0.11 (-4.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Entera Bio Ltd. stock-summary
stock-summary
Entera Bio Ltd.
Pharmaceuticals & Biotechnology
Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism, osteoporosis and bone healing.
Company Coordinates stock-summary
Company Details
Kiryat Hadassah, Minrav Building, Fifth Floor JERUSALEM None : 9112002
stock-summary
Tel: 972 2 5327151
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.06%)

Foreign Institutions

Held by 4 Foreign Institutions (0.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Gerald Lieberman
Independent Chairman of the Board
Dr. Spiros Jamas
Chief Executive Officer, Director
Mr. Zeev Bronfeld
Director
Mr. Sean Ellis
Director
Mr. Yonatan Malca
Director
Ms. Faith Charles
Independent Director
Mr. Gerald Ostrov
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 91 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.08

stock-summary
Return on Equity

-61.44%

stock-summary
Price to Book

5.29